Iconovo AB has completed a directed new share issue of SEK 55 million
The Board of Directors of Iconovo AB (”Iconovo” or the ”Company”) has, in accordance with the intention that was published through a press release earlier today and with the support from the authorisation from the Annual General Meeting on 17 May 2022, resolved on a directed new share issue of 1,375,000 new shares, at a subscription price of SEK 40 per share (the “New Share Issue”). This means that the Company receives SEK 55 million before transaction costs. The subscription price in the New Share Issue has been determined through an accelerated bookbuilding procedure (the ”Bookbuilding”), that was carried out by Danske Bank A/S, Danmark, Sverige Filial (“Danske Bank”). The New Share Issue was subscribed for by a number of institutional investors, including funds managed by Eiffel Investment Group (“Eiffel”).
YEAR-END REPORT JANUARY-DECEMBER 2022
Global interest in Iconovo's proprietary inhaler platform ICOpre® - ready to address the world's largest products for Asthma and COPD
Iconovo AB evaluates the conditions to carry out a directed new share issue of approximately SEK 50 million and brings forward publication of the year-end report for the financial year 2022
Iconovo AB (”Iconovo” or the ”Company”) has mandated Danske Bank A/S, Danmark, Sverige Filial (“Danske Bank”) to evaluate the conditions to carry out a directed new share issue of approximately SEK 50 million (the ”New Share Issue”). The subscription price and the total number of new shares in the New Share Issue will be determined through an accelerated bookbuilding procedure (the “Bookbuilding”) targeting institutional investors. Several current shareholders, among others Eiffel Investment Group (“Eiffel”), have expressed strong support for the New Share Issue and intends to participate in the New Share Issue with significant amounts. Due to the New Share Issue, the Board of Directors has resolved to bring forward the publication of the Company’s year-end report for the financial year 2022. The year-end report will be published directly after this press release.
Iconovo announces positive results in interim report from project with ICOone Nasal®
Iconovo AB (publ), which develops complete inhalation products for a global market, announces positive outcomes in a mid-project report on a project that is funded by Bill & Melinda Gates Foundation. The project aims to develop inhaled therapies based on ICOone Nasal and to establish nasal administration as an efficient route of treatment.
Iconovo receives approval of new European patent for its single-use inhaler ICOone®
Iconovo AB (publ), that develops complete inhalation products for a global market, today announced that the European Patent Office EPO intends to approve Iconovo's patent application for the inhaler platform ICOone® (Communication under Rule 71(3) EPC). The patent describes the company's single-dose inhaler, which is currently being used in three innovative collaborative projects for the administration of e.g., oxytocin and covid-19 vaccine. Iconovo already has a well-established patent portfolio for ICOone® in Sweden, Europe (EPO), the USA, China and India.
Iconovo appoints Henrik Damkjær Simonsen as Chief Financial Officer
Iconovo AB (publ), that develops complete inhalation products for a global market, today announces that Henrik Damkjær Simonsen has been appointed Chief Financial Officer, as of April 1, 2023. He succeeds Peter Åkerlund who has been acting CFO since November 16 of this year.
Iconovo’s ICOone® inhaler platform receives new patent approval in the US
Iconovo AB (publ), that develops inhalation products for a global market, today announced that the United States Patent and Trademark Office (USPTO) intends to approve an additional patent for ICOone® – an innovative inhaler platform that enables convenient and cost-effective administration of vaccines and biologics. Iconovo is already pursuing several development projects based on ICOone®, including one with financial support from the Bill & Melinda Gates Foundation.
Nomination Committee appointed at Iconovo
At the Annual General Meeting of 17 May 2022, it was resolved that Iconovo shall have a Nomination Committee consisting of four members representing the four largest shareholders as of 30 September each year.
Abbreviated interim report 1 January – 30 September
ICOone development supported by Bill & Melinda Gates Foundation
Iconovo’s unique single dose inhaler ICOone® Nasal received high marks in user study
Iconovo AB (publ), that develops inhalation products for a global market, has conducted a user study to assess the handling of its ICOone® Nasal inhaler. The aim is to simplify the usage of ICOone® Nasal so that users can operate it correctly without detailed instructions.